ZyVersa Therapeutics, Inc. (ZVSA)
- Previous Close
5.45 - Open
5.65 - Bid 6.33 x 100
- Ask 6.45 x 100
- Day's Range
5.65 - 6.55 - 52 Week Range
4.44 - 213.50 - Volume
514,160 - Avg. Volume
413,269 - Market Cap (intraday)
4.853M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-1,089.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
70.00
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
www.zyversa.comRecent News: ZVSA
Performance Overview: ZVSA
Trailing total returns as of 5/6/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZVSA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZVSA
Valuation Measures
Market Cap
4.85M
Enterprise Value
1.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.12
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.82%
Return on Equity (ttm)
-177.53%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-106.25M
Diluted EPS (ttm)
-1,089.70
Balance Sheet and Cash Flow
Total Cash (mrq)
3.14M
Total Debt/Equity (mrq)
0.08%
Levered Free Cash Flow (ttm)
-5.46M
Research Analysis: ZVSA
Company Insights: ZVSA
ZVSA does not have Company Insights